2 results
Not approvedWill not start
The objectives of this study are to demonstrate that Nepafenac Ophthalmic Suspension, 0.3% is not inferior to Nepafenac Ophthalmic Suspension, 0.1% (NEVANAC®); Nepafenac Ophthalmic Suspension, 0.3% is superior to Nepafenac 0.3% Vehicle and NEVANAC…
Approved WMOCompleted
The objective is to assess the intra-subject reliability of tDCS induced effects on the reaction time in the lower extremities of healthy subjects.